MedJobScout :: Health :: Medicine :: Medical Specialties :: Hematology :: Associations

All Hematology-Oncology Jobs

Permanent Hematology-Oncology Job in Laurinburg North Carolina with Scotland Memorial Hospital
NORTH CAROLINA HEMATOLOGY/ONCOLOGY OR MEDICAL ONCOLOGY PHYSICIAN OPPORTUNITY AVAILABLE Opportunity to have Duke University Medical Center faculty appointment in thriving, community-based practice.
Permanent Hematology-Oncology Job in SC statewide South Carolina with Medical Doctor Associates, Inc.
Coastal South Carolina Hematology Oncology Opportunity - We are seeking a physician to join a Hematologist Oncologist in his busy two-office private practice. This full-time position offers a competitive
Permanent Hematology-Oncology Job in OH statewide Ohio with Medical Doctor Associates, Inc.
A busy, long established, HEM/ONC practice in central Ohio convenient to Toledo, Dayton, and Columbus is seeking a 3rd physician. You will be busy Day 1 as the group is now overwhelmed by patients. The

Current Opinion in Hematology - Current Table Of Contents

Editorial introductions.
Page: viiDOI: 10.1097/MOH.0b013e32831cc13d
Granulocyte transfusion therapy: a new era?.
Page: 1DOI: 10.1097/MOH.0b013e32831d7953Authors: Dale, David C a; Price, Thomas H b
Advances in diagnosis and treatment of eosinophilia.
Page: 3DOI: 10.1097/MOH.0b013e32831c841fAuthors: Sheikh, Javed a; Weller, Peter F b

Hematological Oncology

Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
Sabine Schreck, Daniela Friebel, Maike Buettner, Luitpold Distel, Gerhard Grabenbauer, Lawrence S. Young, Gerald Niedobitek Wed, 15 Oct 2008 03:59:00 -0000
Classical Hodgkin Lymphoma (cHL) is morphologically characterized by a small number of tumour cells, Hodgkin and Reed-Sternberg (HRS) cells, surrounded by numerous tumour-infiltrating lymphocytes (TIL). The functional role of these TIL is still controversial. While generally considered to represent an anti-tumour immune response, TIL in cHL might result from the profoundly deregulated immunity of cHL patients. Eighty-seven cases of cHL were available to evaluate the prognostical significance of tumour-infiltrating cytotoxic T lymphocytes (CTL), T helper 1 (Th1) cells, T helper 2 (Th2) cells and regulatory T cells (Treg). We confirm that in cHL the microenvironment is dominated by Th2 cells and Treg and show that large numbers of Th2 cells are associated with significantly improved disease-free survival (p = 0.021) and event-free survival (p = 0.012). Furthermore, a high ratio of Treg over Th2 cells resulted in a significantly shortened disease-free survival (p = 0.025). These observations suggest that Treg may exert inhibitory effects on anti-tumour immune responses mediated through Th2 cells and that Th2 cells may be more important for effective anti-tumour immunity than anticipated. Copyright © 2008 John Wiley & Sons, Ltd.
Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT/67gallium scintigraphy abnormality
Akira Kitanaka, Yoshitsugu Kubota, Osamu Imataki, Hiroaki Ohnishi, Tetsuya Fukumoto, Kazutaka Kurokohchi, Terukazu Tanaka Fri, 26 Sep 2008 03:51:00 -0000
Intravascular large B-cell lymphoma (IVLBCL) is a rare lymphoma characterized by the presence of large tumour cells within the blood vessels. It has been considered that IVLBCL is a highly malignant disease with poor prognosis. However, it has been shown that a therapeutic effect resembling that of conventional B-cell lymphomas may be obtained with the application of systemic chemotherapy at the early stage of this disease. Although involvement in the lung is often detected at autopsy, early diagnosis is quite difficult. In this report, we present a case of IVLBCL with pulmonary involvement where 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) was useful in the early diagnosis. Neither computed tomography (CT) nor 67gallium scintigraphy could reveal the presence of disease in the lung. Histological evidence of IVLBCL was obtained by TBLB after FDG uptake in the lung was confirmed by FDG-PET. The patient exhibited a good response to the subsequent combination chemotherapy. We propose that FDG-PET is a powerful tool for the early diagnosis of IVLBCL with pulmonary involvement, if the possibility of this disease presents in the patient with respiratory symptoms without abnormal findings by CT and 67gallium scintigraphy. Copyright © 2008 John Wiley & Sons, Ltd.
Molecular targeting of the PKC-[beta] inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression
Donata Verdelli, Lucia Nobili, Katia Todoerti, Daniela Intini, Maria Cosenza, Monica Civallero, Jessika Bertacchini, Giorgio Lambertenghi Deliliers, Stefano Sacchi, Luigia Lombardi, Antonino Neri Mon, 01 Sep 2008 03:59:00 -0000
The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B-cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin-treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM. Copyright © 2008 John Wiley & Sons, Ltd.

Annals of Hematology

Cardiac involvement in sickle β-thalassemia
Wed, 24 Dec 2008 08:51:14 -0000
Abstract  Cardiovascular involvement is a leading cause of mortality and morbidity in patients with inherited hemoglobinopathies, but it has not been adequately assessed in sickle β-thalassemia. We evaluated 115 sickle β-thalassemia patients, aged 34 ± 14 years, along with 50 healthy controls, by resting echocardiography. Patients with systolic left ventricular (LV) dysfunction or severe pulmonary hypertension (PHT) also underwent left and right cardiac catheterization and cardiac magnetic resonance imaging (CMR). Left and right chamber dimensions, LV mass, and cardiac index were significantly higher in patients compared to controls (p < 0.001 in most cases). Three patients (2.9%) had reduced LV ejection fraction (<55%); mean LV ejection fraction was significantly lower in patients (p < 0.001). Left and right ventricular systolic tissue Doppler indices and LV diastolic tissue Doppler indices were also impaired in patients. All three patients with systolic LV dysfunction had normal coronary arteries and mild myocardial iron load (CMR T2* values, 18–25 ms). Systolic pulmonary artery pressure was significantly higher in patients compared to controls (p = 0.002); PHT was present in 28 patients (27%), while severe PHT in three (2.9%). In three patients with severe PHT, only one had impaired LV ejection fraction and increased pulmonary wedge pressure. Overall, three patients (2.9%) had a history of heart failure, two with systolic LV dysfunction, and one with severe PHT. Cardiac involvement in sickle β-thalassemia concerns biventricular dilatation and dysfunction along with PHT, leading to congestive heart failure. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-008-0661-yAuthors Athanasios Aessopos, Aghia Sophia” Children’s Hospital First Department of Internal Medicine, University of Athens Medical School, “Laiko” General Hospital and the Thalassemia Unit Athens GreeceDimitrios Farmakis, Aghia Sophia” Children’s Hospital First Department of Internal Medicine, University of Athens Medical School, “Laiko” General Hospital and the Thalassemia Unit Athens GreeceChristos Trompoukis, Aghia Sophia” Children’s Hospital First Department of Internal Medicine, University of Athens Medical School, “Laiko” General Hospital and the Thalassemia Unit Athens GreeceMaria Tsironi, Aghia Sophia” Children’s Hospital First Department of Internal Medicine, University of Athens Medical School, “Laiko” General Hospital and the Thalassemia Unit Athens GreeceIoannis Moyssakis, Aghia Sophia” Children’s Hospital First Department of Internal Medicine, University of Athens Medical School, “Laiko” General Hospital and the Thalassemia Unit Athens GreecePanagiotis Tsaftarides, Aghia Sophia” Children’s Hospital First Department of Internal Medicine, University of Athens Medical School, “Laiko” General Hospital and the Thalassemia Unit Athens GreeceMarkisia Karagiorga, Aghia Sophia” Children’s Hospital First Department of Internal Medicine, University of Athens Medical School, “Laiko” General Hospital and the Thalassemia Unit Athens Greece Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type
Wed, 24 Dec 2008 08:51:14 -0000
Abstract  There is no standard salvage regimen for patients with refractory and relapsed extranodal NK/T-cell lymphoma (NKTCL), nasal type. This study was conduced to evaluate the efficacy of L-asparaginase-based regimen as a salvage regimen, on refractory and relapsed extranodal NKTCL, nasal type. Between March 1996 and March 2008, 45 patients with refractory and relapsed extranodal NKTCL, nasal type, were studied retrospectively. All patients were treated with L-asparaginase-based salvage regimen. Thirty-nine patients also received primary involved-field radiation after L-asparaginase-based chemotherapy. The complete response rate, partial response rate, and overall response rate for the whole group were 55.6%, 26.7%, and 82.2%, respectively. Both of 3-year and 5-year overall survival (OS) rates were 66.9%. The major adverse effects of L-asparaginase were myelosuppression, liver dysfunction, hyperglycemia, and allergic reaction. In general, the side effects could be tolerated. On univariate analysis, age, the stage of disease, and performance status were found to be prognostic factors influencing OS. On multivariate analysis, the stage of disease and age were independent prognostic factors for OS. L-Asparaginase-based regimen was obviously effective for the patients with refractory and relapsed extranodal NKTCL, nasal type. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-008-0669-3Authors Weiben Yong, Peking University Department of Medical Oncology, Beijing Cancer Hospital & Institute, the School of Oncology 52# Fucheng Road Beijing 100036 People’s Republic of ChinaWen Zheng, Peking University Department of Medical Oncology, Beijing Cancer Hospital & Institute, the School of Oncology 52# Fucheng Road Beijing 100036 People’s Republic of ChinaJun Zhu, Peking University Department of Medical Oncology, Beijing Cancer Hospital & Institute, the School of Oncology 52# Fucheng Road Beijing 100036 People’s Republic of ChinaYuntao Zhang, Peking University Department of Medical Oncology, Beijing Cancer Hospital & Institute, the School of Oncology 52# Fucheng Road Beijing 100036 People’s Republic of ChinaXiaopei Wang, Peking University Department of Medical Oncology, Beijing Cancer Hospital & Institute, the School of Oncology 52# Fucheng Road Beijing 100036 People’s Republic of ChinaYan Xie, Peking University Department of Medical Oncology, Beijing Cancer Hospital & Institute, the School of Oncology 52# Fucheng Road Beijing 100036 People’s Republic of ChinaNingjing Lin, Peking University Department of Medical Oncology, Beijing Cancer Hospital & Institute, the School of Oncology 52# Fucheng Road Beijing 100036 People’s Republic of ChinaBo Xu, Peking University Department of Radiation Oncology, Beijing Cancer Hospital & Institute, the School of Oncology Beijing People’s Republic of ChinaAiping Lu, Peking University Department of Pathology, Beijing Cancer Hospital & Institute, the School of Oncology Beijing People’s Republic of ChinaJiyou Li, Peking University Department of Pathology, Beijing Cancer Hospital & Institute, the School of Oncology Beijing People’s Republic of China Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
A complex 1;19;11 translocation involving the MLL gene in a patient with congenital acute monoblastic leukemia identified by molecular and cytogenetic techniques
Wed, 24 Dec 2008 08:51:14 -0000
A complex 1;19;11 translocation involving the MLL gene in a patient with congenital acute monoblastic leukemia identified by molecular and cytogenetic techniques Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-008-0656-8Authors Etienne De Braekeleer, Université de Bretagne Occidentale Laboratoire de Cytogénétique, Faculté de Médecine et des Sciences de la Santé 22, avenue Camille Desmoulins CS 93837 F-29238 Brest Cedex 3 FranceClaus Meyer, JWG-University of Frankfurt Institute of Pharmaceutical Biology/DCAL/ZAFES Frankfurt/Main GermanyNathalie Douet-Guilbert, Université de Bretagne Occidentale Laboratoire de Cytogénétique, Faculté de Médecine et des Sciences de la Santé 22, avenue Camille Desmoulins CS 93837 F-29238 Brest Cedex 3 FranceFrédéric Morel, Université de Bretagne Occidentale Laboratoire de Cytogénétique, Faculté de Médecine et des Sciences de la Santé 22, avenue Camille Desmoulins CS 93837 F-29238 Brest Cedex 3 FranceMarie-Josée Le Bris, Hôpital Morvan Service de Cytogénétique, Cytologie et Biologie de la Reproduction CHU Brest FranceRolf Marschalek, JWG-University of Frankfurt Institute of Pharmaceutical Biology/DCAL/ZAFES Frankfurt/Main GermanyClaude Férec, Institut National de la Santé et de la Recherche Médicale (INSERM) U613 Brest FranceMarc De Braekeleer, Université de Bretagne Occidentale Laboratoire de Cytogénétique, Faculté de Médecine et des Sciences de la Santé 22, avenue Camille Desmoulins CS 93837 F-29238 Brest Cedex 3 France Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555

American Journal of Hematology

Urinary cysteinyl leukotriene E4 is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease
Joshua J. Field, James Krings, Nicole L. White, Yan Yan, Morey A. Blinder, Robert C. Strunk, Michael R. DeBaun Tue, 02 Dec 2008 13:25:00 -0000
Leukotriene E4 (LTE4) levels are associated with rate of pain episodes in children with sickle cell disease (SCD). Because complications of SCD manifest differently in adults than children, we examined a cohort of adults with SCD to determine the relationship between baseline LTE4 and SCD-related morbidity. Baseline LTE4 levels were associated with increased rates of pain and acute chest syndrome (ACS) episodes, when those with LTE4 values in the highest tertile were compared with those in the lowest tertile (pain: risk ratio 7.1, 95% CI 1.8-27.5, P = 0.005; ACS: risk ratio 12.2, 95% CI 2.1-69.8, P = 0.005). Am. J. Hematol., 2009. © 2009 Wiley-Liss, Inc.
Prognostic significance of [beta]-catenin and topoisomerase II[alpha] in de novo acute myeloid leukemia
Chih-Cheng Chen, Jyh-Pyng Gau, Jie-Yu You, Kuan-Der Lee, Yuan-Bin Yu, Chang-Hsien Lu, Jen-Tsun Lin, Chieh Lan, Wan-Hsia Lo, Jacqueline Ming Liu, Ching-Fen Yang Mon, 10 Nov 2008 11:50:00 -0000
The Wnt/[beta]-catenin signaling is important for controlling self-renewal of hematopoietic stem cells and its constitutive activation has recently been documented in a significant proportion of acute myeloid leukemia (AML) cases. Topoisomerase II[alpha] (Topo II[alpha]) is a marker of cell proliferation and a crucial target for anthracycline cytotoxicity, the mainstay of management employed in AML. We retrospectively investigated the prognostic roles of [beta]-catenin and topo II[alpha] in a cohort of 59 patients with newly diagnosed AML by immunohistochemistry. Aberrant [beta]-catenin expression was demonstrated in 13 patients (22%), and it was more likely to occur in those with unfavorable karyotypes. Advanced age and poor performance status adversely influenced the achievement of complete remission, while neither aberrant [beta]-catenin expression nor enhanced topo II[alpha] activity did. On multivariate survival analysis, four factors independently predicted a shortened overall survival: aberrant [beta]-catenin expression, high topo II[alpha] activity, poor-risk cytogenetics, and presence of at least one comorbidity factor. Our results suggest that both [beta]-catenin and topo II[alpha] independently predicted an adverse prognosis and might serve as new markers for risk stratification in AML patients. Am. J. Hematol., 2009. © 2009 Wiley-Liss, Inc.
Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation
Cristina Mihaela Precupanu, Jacques Girodet, Pascale Mariani, Manuela Zanni, Claire Mathiot, Marie-Christine Escande, Philippe Brault, Didier Decaudin Wed, 08 Oct 2008 16:52:00 -0000
No abstract.

Pediatric Hematology and Oncology: Articles recently published in

SAFETY OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN LESS THAN THREE YEARS OF AGE
Matthews, Edward W.Kristovich, Karen M.Wong, Wendy B.Wright, Nicola BobeyDvorak, Christopher C.Agarwal, RajniAmylon, Michael D.Weinberg, Kenneth I. Sat, 01 Nov 2008 00:00:00 -0000

PLASMA NATRIURETIC PEPTIDES LEVELS AND ECHOCARDIOGRAPHIC FINDINGS IN LATE SUBCLINICAL ANTHRACYCLINE TOXICITY
Kansoy, SavasAksoylar, SerapOzyurek, RuhiCetingul, NazanLevent, ErturkKantar, MehmetUlger, Zulal Sat, 01 Nov 2008 00:00:00 -0000

PULMONARY HYPERTENSION IN β-THALASSEMIA MAJOR AND THE ROLE OF L-CARNITINE THERAPY
Youssry, IlhamEl-Beshlawy, AmalEl Accaoui, RamziMansi, YassminMakhlouf, AliTaher, AliEl-Saidi, Sonia Sat, 01 Nov 2008 00:00:00 -0000


Subscribe to Associations RSS feed